HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Consumer Supply Chain Prowess Helps Offset Inflationary Pressures For Record Results

Executive Summary

After a company-record FY2022, Prestige CEO Ron Lombardi says future inflationary pressures and supply chain issues should be “manageable.”

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't

Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.

Prestige Consumer’s ‘Nimble’ Marketing Helps Beat Fiscal 2021 Guidance

Less travel, closed schools and a slower cold/cough season during the pandemic required Prestige Consumer to invest strategically across its OTC healthcare portfolio in fiscal 2021. Dramamine motion sickness and Nix head lice treatments got less attention, while Monistat, Compound W and Clear Eyes received more.

Topics

Related Companies

UsernamePublicRestriction

Register

RS152490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel